Pharmacologic Substance – Page 119

Pheon Secures $120 Million in Series B Funding to Revolutionize Treatment for Challenging Cancers with Advanced Antibody-Drug Conjugates

11 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Biotechnology, Cancer Therapeutic Procedure, hard-to-treat cancers, healthcare innovation, Pheon, Series B

Pheon, Series B funding, $120 million, hard-to-treat cancers, antibody-drug conjugates (ADCs), cancer treatment, biotechnology, healthcare innovation.

Biopharma Downsizing Trends 2024: Major Companies Adjusting Workforce

11 months ago talkbio0Tagged Biopharma, Industry, Takeda, trends qualifier

Biopharma, layoffs, downsizing, workforce reduction, Evotec, Lyra Therapeutics, Takeda Pharmaceuticals, industry trends, 2024

Tremfya Emerges as a Promising Successor to Stelara in J&J’s Pipeline with Robust Clinical Data

11 months ago talkbio0Tagged Biological Factors, Clinical Trials, head-to-head data, J&J, Psoriasis, Stelara, successor, Tremfya

J&J, Tremfya, Stelara, successor, head-to-head data, clinical trials, psoriasis treatment, biologics.

Lilly Expands Radiopharmaceutical Portfolio with Aktis Acquisition

11 months ago talkbio0Tagged Acquisition (action), Aktis, Cancer Therapeutic Procedure, cellular targeting, Eli Lilly, portfolio, Radiopharmaceuticals

Lilly, Aktis, radiopharmaceutical, acquisition, portfolio, cancer therapy, targeted treatment

AltruBio Secures $225 Million for Phase II Trials of Novel Immune Checkpoint Enhancing Antibody

11 months ago talkbio0Tagged AltruBio, Antibodies, Biotechnology, Cancer Therapeutic Procedure, healthcare innovation, Immune, Immunotherapy, Phase 2 Clinical Trials

AltruBio, funding, Phase II trials, immune checkpoint enhancing antibody, cancer treatment, immunotherapy, biotechnology, healthcare innovation.

AstraZeneca Invests $1.5 Billion in Singapore for Comprehensive Antibody-Drug Conjugate Manufacturing

11 months ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, Biotechnology, Cancer Therapeutic Procedure, end-to-end, Investments, Manufacture, production, Singapore

AstraZeneca, Singapore, antibody-drug conjugate (ADC), manufacturing, investment, biotechnology, pharmaceuticals, end-to-end production, cancer treatment.

FDA Greenlights Biocon Biologics and Biogen’s Eylea Biosimilars: A New Era in Ophthalmology

11 months ago talkbio0Tagged Biocon, Biogen, Biological Factors, Biosimilars, Eylea, Ophthalmology specialty, regulatory approval, United States Food and Drug Administration

FDA, Eylea, biosimilars, Biocon Biologics, Biogen, ophthalmology, aflibercept, regulatory approval

AstraZeneca’s Ambitious Vision: Pursuing $80 Billion in Revenue and 20 New Drugs by 2030

11 months ago talkbio0Tagged AstraZeneca, Biotechnology, Drug Development, Drug Industry, expansion, growth strategy, healthcare innovation, Market

AstraZeneca, revenue target, new drugs, 2030, growth strategy, pharmaceutical industry, healthcare innovation, biotechnology, drug development, market expansion.